On July 21, 2022, Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public offering price of $27.00 per share, for total gross proceeds of approximately $225.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Verve. All of the shares in the offering are being sold by Verve. In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,250,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on July 25, 2022, subject to the satisfaction of customary closing conditions.

A Wilson Sonsini Goodrich & Rosati team that advised Verve Therapeutics on IP matters related to the transaction includes Vern Norviel, Clark Lin, and Angel Wang.

For more information, please see Verve Therapeutics' press release.